Overview

This trial is active, not recruiting.

Condition burns
Treatments selenium1, selenium2, placebo
Phase phase 4
Sponsor Shriners Hospitals for Children
Start date January 2009
End date January 2018
Trial size 14 participants
Trial identifier NCT00860379, 2007-P-001176

Summary

The selenium status of children with major burns is suboptimal which may increase the incidence of infection. Se requirements during critical illness are not known. Results from this investigation may provide a tool for recommending Se supplements during burn injury.

The hypothesis of this research is that Se supplementation will restore the depressed Se status among children with burn injuries. The secondary hypothesis is that Se status is related to the incidence of infection among pediatric patients with burns.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose prevention
Arm
(Placebo Comparator)
Placebo
placebo saline
IV saline as placebo
(Experimental)
Subject will receive 2 ug/kg of IV selenium per day
selenium1
2 ug/kg
(Experimental)
Subject will receive 4 ug/kg of IV selenium per day
selenium2
4 ug/kg

Primary Outcomes

Measure
plasma selenium, plasma glutathione peroxidase, urine selenium
time frame: weekly

Secondary Outcomes

Measure
infection
time frame: daily

Eligibility Criteria

Male or female participants from 1 year up to 18 years old.

Inclusion Criteria: - Between 1 and 18 years of age admitted to Shriners Burns Hospital - TBSA burn of > 20% - Existing IV catheter - Enrolled into study within 3 weeks of burn injury Exclusion Criteria: - < 1 year or > 18 years of age - < 20% TBSA burn - No existing IV catheter - Pre-existing or acute renal disease (creatine > 1.5 mg/dl) - Pre-existing or acute liver disease (bilirubin > 3) - Pre-existing or acute thyroid disorders - Cancer - AIDS - Pregnancy (as determined by routine admission labs)

Additional Information

Official title The Effect of Selenium Supplementation Among Pediatric Patients With Burns
Principal investigator Maggie L Dylewski, PhD,RD
Description Study Title: The effect of selenium supplementation among pediatric patients with burns Primary Investigator: Maggie L. Dylewski, PhD, RD Co-investigators: RL. Sheridan, MD; C Ryan, MD; K Prelack, PhD,RD; M Lydon, RN; J Weber, RN, BSN, CIC Approved by: FDA (IND # 78963), Partners IRB (#2007-P-001176). Funding: private grant from the Boston Burn Foundation Background Information: Selenium, an essential dietary nutrient, is a component of glutathione peroxidase (an antioxidant) and thioredoxin reductase, an enzyme that regulates cytokine expression and thus plays a role in the immune system. Previous studies among adult burn patients showed that IV selenium supplementation was related to decreased infection and mortality. Please refer to the study protocol for further details. Previous Research: We previously showed that children with burns (n = 20) > 20% TBSA had low plasma selenium values compared to reference data of healthy American children. Results from this study also found a significant relationship between plasma selenium and incidence of infections. Study Design: Randomized, double-blind, placebo-controlled clinical trial Specific Aims: 1. to determine the impact of supplemental selenium on plasma selenium, glutathione peroxidase activity, and urine selenium among pediatric patients with burns >20% TBSA. 2. to determine the association between selenium supplementation, biomarkers of Se status and indicators of stress and infection. Subjects: N = 75 pediatric patients with burns. Inclusion criteria: - Between 1 and 18 years of age admitted to Shriners Burns Hospital - TBSA burn of > 20% - Existing IV catheter - Enrolled into study within 3 weeks of burn injury Treatment: All subjects will be randomized into 1 of 3 groups and receive the treatment for 8 weeks, until 95% wound closure, or until central venous catheter access is discontinued. 1. Placebo (IV 0.9% sodium chloride) 2. 2 mcg/kg/day IV Selenium 3. 4 mcg/kg/day IV Selenium Biological sample collection: - 4 mL or 8 mL (8 every other week) of plasma once a week - 24-hour urine collection once a week Sample analyses: - Samples will be frozen until analyses - Samples will be sent to the outside lab for analyses. - Plasma will also be sent to Massachusetts General Hospital every other week for plasma selenium analysis (to assess for toxicity) Primary outcome measures: - Plasma selenium - Plasma glutathione peroxidase - Urine selenium Secondary outcome measures: • occurrence of pneumonia or infection (bacterial or fungal) in the wound, blood, or urine Risks: - Supplement doses were determined using data from previous studies, current RDAs and upper tolerable limits, ASPEN guidelines for parenteral selenium, and dietary data recorded from our previous study. According to reference weights (NHANES III) supplement doses do not exceed the upper tolerable limits for children. - Selenium toxicity is rare. However plasma will be assessed every other week for selenium levels. Monitoring and Quality Assurance: - All subjects will be monitored for any treatment-related adverse events for 2 weeks following discontinuation of the study therapy - Any adverse events will be reported to the Partners Human Research Committee and the FDA per the guidelines. An independent Data Safety Monitoring Board, consisting of 4 knowledgeable staff members, will meet 2 times per year to monitor the data for safety.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Shriners Hospitals for Children.